Comtan (entacapone) / Novartis, Orion Corp, Alvogen - LARVOL DELTA

Exploratory Clinical Study ofEntacapone Combined with PD-1/L1 Antibody andTargeted Therapy in Advanced Hepatocellular Carcinoma Refractory to StandardTreatment (ChiCTR) - P=N/A | N=32 | Recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database. (PubMed, Arq Neuropsiquiatr) - "The most used medications were pramipexole (45.6%), amantadine (26.0%), and entacapone (17.1%).The present study provides valuable insights into the demographic and clinical profile of PD patients in Brazil, highlighting frequent procedures and treatment patterns. A key limitation is the non-capture of basic PD medications, such as levodopa, which are often dispensed outside the analyzed datasets. These findings underscore the need for improved data integration and access to comprehensive PD care within the public health system."

HEOR • Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

EFFICACY OF MAO-B AND COMT INHIBITORS ON QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE: A BAYESIAN NETWORK META-ANALYSIS (ADPD 2026) - "Randomized controlled trials evaluating QoL using PDQ-39 or PDQ8 in patients treated with MAO-B inhibitors (rasagiline, selegiline, safinamide) or COMT inhibitors (entacapone, opicapone, tolcapone) were included. This network meta-analysis provides evidence that MAO-B inhibitors, particularly rasagiline and safinamide, may offer broader QoL benefits in patients with PD, especially in NMS such as emotional well-being. These findings support a more symptom-oriented and individualized treatment approach should be provided to patients with PD. Further well-designed head-to-head studies using standardized QoL measures and extended follow-up are needed to confirm these findings and guide clinical practice."

HEOR • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

EFFECTS OF MAO-B AND COMT INHIBITORS ON SLEEP DISTURBANCES IN PARKINSON'S DISEASE: A NETWORK META-ANALYSIS (ADPD 2026) - "Inclusion criteria involved (1) patients with PD, (2) intervention/comparator consisting of MAO-B inhibitors (safinamide, rasagiline, or selegiline) and COMT inhibitors (opicapone, entacapone, or tolcapone), and (3) outcomes of improvement in parameters for subjective and objective sleep in randomized controlled trials and cohort studies. Evidence has shown that safinamide is effective in improving objective sleep parameters in patients with PD. However, given the paucity of evidence and controlled, long-term studies, the effects of MAO-B and COMT inhibitors on sleep disturbances remain unclear. More high-quality studies will be needed and should enable clinicians to provide personalized medicine based on sleep profiles."

Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder • COMT

CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease. (PubMed, Res Sq) - "Twenty drugs showed consistent protective associations, with four emerging as highly reproducible across both networks, the metabolic agents liraglutide and empagliflozin and the neuroactive agents entacapone and amantadine. Metabolic drugs produced the strongest benefits in individuals with diabetes, obesity, or cardiovascular disease, whereas neuroactive drugs provided broadly consistent protection across most subgroups.CauReL is available as an open source Python package with a companion web server for direct application to new cohorts or disease settings (https://caurel.site/). This work delivers a scalable and interpretable framework for prioritizing repurposable drugs and designing targeted clinical trials for the patients most likely to benefit."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Taxonomic and mechanistic insights into gut microbiota bioaccumulation of entacapone using bioorthogonal drug labelling. (PubMed, Microbiome Res Rep) - " Our findings reveal that entacapone is widely bioaccumulated by the gut microbiota across three donors and identify a key molecular mediator of this accumulation. This study expands the toolkit for investigating drug-microbiome interactions and holds significant potential to advance our understanding of drug-microbiome dynamics and therapeutic outcomes."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Epigenetic regulation of NAFLD: A preclinical study. (PubMed, Indian J Med Res) - "Pharmacological inhibition of mFTO by entacapone restored m6A marks on gene transcripts and reversed the NAFLD phenotype. Interpretation & conclusions Gene expression profiling identified key metabolic pathways and molecular targets associated with NAFLD progression. It underscored the role of mFTO in altering the m6A methylation landscape essential for establishing NAFLD and highlighted its therapeutic potential for NAFLD-associated morbidities."

Journal • Preclinical • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Effects of Combined Entacapone and rTMS Therapy on Pain Severity and Serum Inflammatory Biomarkers (IL-6 and TNF-α) in Parkinson's Disease. (PubMed, Brain Res Bull) - "High-frequency rTMS, as a non-invasive neuromodulation technique combined with EN, improves muscle rigidity, alleviates depressive symptoms, reduces pain, and attenuates inflammatory factor secretion in PD patients, can improve muscle tension, regulate depression, relieve pain, and reduce the secretion of inflammatory factors in Parkinson's patients.This combined therapy was clinically effective and demonstrated a favorable safety profile, with no serious adverse events reported and only mild, transient side effects (e.g., scalp discomfort, headache) observed in the rTMS group. However, its long-term efficacy requires further investigation."

Biomarker • Journal • CNS Disorders • Depression • Movement Disorders • Oncology • Pain • Parkinson's Disease • Psychiatry • IL6 • TNFA

Voltammetric analysis of entacapone, levodopa, and carbidopa in tablets: A chemometric approach. (PubMed, J Pharm Biomed Anal) - "The objective of the present work is to develop a voltammetric method for the determination of entacapone (ENT) in the presence of levodopa (LEV) and carbidopa (CAR) in synthetic mixtures and pharmaceutical formulations, using a multivariate approach. To evaluate the validity of the recommended method, a commercial pharmaceutical tablet (Stalevo ® 200 mg) was analyzed. RBF model has the ability to overcome difficulties such as non-linearity and overlaps in the voltammograms."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

A Randomized, Open-Label, Single-Dose, Two-Sequence, Four-Period, Replicate Crossover Bioequivalence Study of Entacapone Tablets in Fasting and Fed States Among Healthy Chinese Participants. (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University

New trial • CNS Disorders • Movement Disorders • Parkinson's Disease

The possible protective effect of entacapone on hepatic fibrosis via the fat mass and obesity-associated protein/ N6-methyladenosine/ silent information regulator 1 pathway in a rat model. (PubMed, J Pharmacol Exp Ther) - "The current study may offer entacapone as a promising approach for liver protection during fibrosis. SIGNIFICANCE STATEMENT: The current study suggests that entacapone could increase silent information regulator 1 expression through its effect on fat mass and obesity-associated protein and N6-methyladenosine modulation, providing a promising approach for protecting the liver during fibrosis and identifying a potential new molecular target for the prevention of liver fibrosis."

Journal • Preclinical • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Obesity • FTO

Infusion therapies for Parkinson's disease: where are we in 2025? (PubMed, Expert Opin Drug Deliv) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Treatment Of Advanced Parkinson's With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia (MDS Congress 2025) - P | "Data from ELEGANCE suggest that long-term treatment with LECIG can improve the daily duration of dyskinesia. In the small number of patients who switched from LCIG to LECIG, there was a trend for a slight reduction in daily hours of dyskinesia. Figure 1 Figure 2"

Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Sustained Motor Symptom Efficacy With Long-Term Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Treatment – Data From The ELEGANCE Interim Analysis (MDS Congress 2025) - P | "LECIG showed sustained clinical efficacy in reducing PD motor symptoms, both during the day and at night, following treatment for up to two years. Figure 1 Figure 2 Figure 3"

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis (MDS Congress 2025) - P | "These data suggest that LECIG treatment for up to one year is generally well tolerated by patients with advanced PD. As has been observed with levodopa–carbidopa intestinal gel infusion, the most frequent AEs are associated with the procedure or the device. Table 1"

Adverse events • CNS Disorders • Movement Disorders • Parkinson's Disease

Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson's Disease (MDS Congress 2025) - "The therapeutic efficacy of LECIG in mitigating motor complications is comparable to that of levodopa–carbidopa intestinal gel (LCIG), with the added benefits of a reduced daily levodopa requirement and a more compact administration device. However, further longitudinal studies and extended clinical experience are required to determine the relative advantages of these two enteral levodopa formulations within the framework of personalized treatment strategies for advanced Parkinson's disease."

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Motor Fluctuations in Parkinsons Disease and their Correction (MDS Congress 2025) - "All patients with motor fluctuations were prescribed combination therapy with Dopalevo (levodopa 200 mg + carbidopa 25 mg + entacapone 200 mg), previously these patients were taking Nacom ( levodopa 250 + carbidopa 25 mg). Motor fluctuations in Parkinson's disease lead to a decrease in the functional status of patients, having a significant impact on their quality of life. Most often these motor disturbances are observed in patients with earlier disease debut. Inclusion of entacapone in the antiparkinsonian therapy regimen promotes improvement of motor functions, which may contribute to the overall effectiveness of treatment."

CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson's – Data From The ELEGANCE Interim Analysis (MDS Congress 2025) - P | "Both clinicians and PD patients report sustained favourable improvements in their disease following treatment with LECIG for up to two years compared with their baseline condition. Figure 1 Figure 2"

Clinical • Metastases • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Safety and tolerability of overnight switching from Eetacapone to Opicapone in fluctuating Parkinson's disease: An open-label preliminary trial in Koreans (MDS Congress 2025) - "An overnight switching of entacapone to opicapone is safe and well tolerated. The majority of subjects preferred opicapone due to reducing off time with peak dose dyskinesia and the convenience."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson's Disease: Perspectives of Patients, Clinicians, and Caregivers (MDS Congress 2025) - "LECIG therapy significantly reduces caregiver burden and improves patient-reported quality of life in PD. Clinician assessments corroborate these benefits, with no reported worsening. These findings highlight the importance of continuous dopaminergic stimulation in managing advanced PD."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Deep Brain Stimulation (DBS) Placement in a Patient with Parkinson's disease (PD) and Polyostotic Fibrous Dysplasia (PFD) (MDS Congress 2025) - "Multiple medications in his regimen were rasagiline, levodopa (immediate and controlled release), pramipexole and entacapone. DBS candidates with PD and a history of PFD can be evaluated, implanted and programmed."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Six Months Analysis Of REONPARK Study (MDS Congress 2025) - " One hundred and thirty-one evaluable patients (mean±SD: 65.2±10 years old; 5.1±3.2 years PD duration; 472.9±196 mg/daily L-dopa/DDCI; MDS-UPDRS III:22.5±14.3; MDS-UPDRS IV:2.9±2.1) initiated COMTi (99.3% opicapone; 0.7% entacapone). COMTi (mainly opicapone) treatment demonstrated a reduction on OFF time and motor complications, improving the functional impact of fluctuations after 6 months of treatment in real-world practice. Table 1 Figure 1 Figure 2"

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Three Months Analysis Of REONPARK Study (MDS Congress 2025) - "Presenting here an interim analysis up to 3 months post COMTi initiation One hundred and thirty-eight evaluable patients (mean±SD: 65.4±10 years old; 5.3±3.5 years PD duration; 474.3±197 mg/daily L-dopa/DDCI; MDS-UPDRS III:23.7±14.4; MDS-UPDRS IV:3.0±2.1) initiated COMTi (99.3% opicapone; 0.7% entacapone). COMTi (mainly opicapone) treatment demonstrated a reduction on OFF time and motor complications, improving the functional impact of fluctuations after 3 months of treatment in real-world practice. Table 1 Figure 1 Figure 2"

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Comparative efficacy of opicapone and entacapone in the management of motor fluctuations in Parkinson's disease (MDS Congress 2025) - "Compared to ENT, OPC provides numerically higher reduction of "Off" time, increased "On" time, and a higher proportion of patients reporting meaningful clinical improvement. The benefit was maintained in the OLE study, further supporting its long-term efficacy. These findings suggest that OPC's once-daily dosing offers an effective and convenient option for optimizing LD therapy in patients with PD."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Comparative Analysis of miR-29a Expression in Optimized Medical Therapy and Intestinal Infusion Therapies in Advanced Parkinson's Disease (MDS Congress 2025) - "Objective: To compare the relative expression of miR-29a in patients with advanced Parkinson's disease (PD) receiving optimized medical therapy (OMT) versus intestinal infusion therapies—levodopa/carbidopa intestinal gel (LCIG) and levodopa/entacapone/carbidopa intestinal gel (LECIG). In our study, we observed that there was a significant decrease in the relative expression of miR-29a in patients on OMT. This decrease may be associated with greater dopamine level fluctuations, potentially contributing to increased oxidative stress. The stable miR-29a expression in the intestinal infusion groups (LCIG and LECIG) could suggest a neuroprotective effect of continuous levodopa administration, potentially mitigating neuronal stress and inflammation."

Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease • MIR29A